Bosulif, a new leukemia treatment, is expected to receive reimbursement next year.

According to the pharmaceutical industry, Pfizer Korea successfully completed drug pricing negotiations with the National Health Insurance Service for Bosulif (bosutinib), a Chronic Myelogenous Leukemia (CML) treatment.

Bosulif will be presented to the Health Insurance Policy Review Committee of the Ministry of Health and Welfare, and if approved, it will be reimbursed starting in January 2024.

Following its FDA approval in 2012, Bosulif was authorized for use much later in Korea, in last January.

Bosulif is a second-generation targeted therapy similar to Novartis Korea’s